

1-Thiacyclooct-4-yne (= 5,6-Didehydro-3,4,7,8-tetrahydro-2*H*-thiocin), and Its Sulfoxide and Its Sulfone


by Hans Schuhmacher, Bernhard Beile, and Herbert Meier*

Institute of Organic Chemistry, University of Mainz, Duesbergweg 10–14, D-55099 Mainz
(phone: +49-6131-3922605; fax: +49-6131-3925396; e-mail: hmeier@uni-mainz.de)

1-Thiacyclooct-4-yne (= 5,6-didehydro-3,4,7,8-tetrahydro-2*H*-thiocin; **9**) can be prepared from thiocan-5-one (**6**) in three steps by applying the so-called selenadiazole method. The heterocyclic alkyne can be oxidized to the corresponding sulfoxide **16** and sulfone **17**. Due to their geometrical strain, all three cyclic alkynes show high reactivities in *Diels–Alder* and 1,3-dipolar cycloadditions. Moreover, tetrathiafulvalenes can be prepared from **9** and **16** by the reaction with CS₂.


Introduction. – Due to their high reactivity in addition and cycloaddition reactions, strained cycloalkynes have a high actuality in click processes and bioorthogonal reactions [1–14]. In the previous five years, many studies of azacyclooct-5-yne (**1**) appeared [8][11][15–42].

To the best of our knowledge, only one example exists for 1-oxacyclooct-4-yne (**2**) and one for 1-thiacyclooct-4-yne **3**, namely the tricyclic lactone **4** [42] and the bicyclic sulfone **5** [43], respectively. This prompted us to report our results on the parent compound **3**.




Results and Discussion. – A convenient and high-yield preparation of strained cyclic alkynes is based on the fragmentation of 1,2,3-selenadiazoles [44]. We used the conversion of thiocanone **6** to the 1,2,3-selenadiazole **8** *via* the semicarbazone **7** [45]. Thermolysis of **8** on Cu powder gave the desired 1-thiacyclooct-4-yne (= 5,6-didehydro-3,4,7,8-tetrahydro-2*H*-thiocin; **9**) in almost quantitative yields (*Scheme 1*).

The 1,2,3-selenadiazole ring is sensitive towards oxidation. Therefore, we tried to oxidize its precursor, the thiocanone **6** with NaIO₄ to the sulfoxide **10** and with H₂O₂ to the sulfone **11**. The corresponding 1,2,3-selenadiazoles **14** and **15** were then obtained *via* the semicarbazones **12** and **13**, respectively. However, the thermal fragmentation of **14** and **15** failed. The volatility of the desired products is not high enough, so that decompositions occurred in the hot zone.

Scheme 1. Preparation of 5-Thiacyclooctyne (**9**), and Its Sulfoxide (**16**) and Its Sulfone (**17**)

i) $\text{H}_2\text{NNHCONH}_2$, EtOH, AcONa. *ii)* SeO_2 , aqueous dioxane. *iii)* Cu, 165–175°, 100 Pa. *iv)* NaIO_4 , 0°.

Therefore, we tried the alkaline fragmentation of the 1,2,3-selenadiazole **14** with BuLi. The reaction led to a mixture of several Se-containing products. Selenio sulfoxide **18** was the major component, and the desired alkyne **16** was a minor product, in an unsatisfying yield (Scheme 2).



Finally, we realized that the stability of 1-thiacyclooct-4-yne (**9**) is sufficient for the oxidation to its sulfoxide **16** and its sulfone **17**. A fourfold excess of NaIO_4 yielded 80% of the oxidation-productmixture **16/17** in a 43:37 ratio (Scheme 1). A higher excess of NaIO_4 increased the portion of the sulfone **17**, but reduced the overall yield.

One- and two-dimensional NMR experiments were performed for the characterization of the new alkynes. A $^1\text{H}, ^1\text{H}$ -shift-correlated NMR spectrum of *rac*-**16** is depicted in the Figure. The COSY 45 technique is suitable to distinguish between the geminal and vicinal couplings [46]. A control for the assignment of geminal H-atoms was achieved by a HSQC measurement.





Figure. $^1\text{H},^1\text{H}$ -COSY-45-NMR Spectrum of rac-**16**. The cross-peaks, which are characterized by a positive slope, correspond to vicinal couplings, the cross-peaks marked with a negative slope correspond to geminal couplings.

The ^1H and ^{13}C chemical shifts of the alkynes **9**, **16**, and **17** are compiled in the *Table*.


An easy anchor point for the interpretation of the NMR spectra is always $\text{CH}_2(3)$ with two adjacent CH_2 groups, $\text{CH}_2(2)$ and $\text{CH}_2(4)$. Due to the geometrical strain, the sp -atoms $\text{C}(5)$ and $\text{C}(6)$ exhibit signals with relatively high δ values. Their difference $\Delta\delta$ is small, which is in accordance with the small polarization of the $\text{C}\equiv\text{C}$ bonds and the small regioselectivity of certain cycloadditions shown below.

The strain energies of the eight-membered rings of **9**, **16**, and **17** should be comparable to that of cyclooctyne [44]. Hence, a high reactivity of **9**, **16**, and **17** in cycloaddition reactions can be expected. We studied first the reactions with 2,3,4,5-tetraphenylcyclopenta-2,4-dienone (**19**) at room temperature (*Scheme 3*). The *Diels*–

Table. ^1H - and ^{13}C -NMR (CDCl_3) Data of the Heterocyclic Alkynes **9**, **16**, and **17**. δ in ppm relative to Me_4Si as internal standard, J in Hz. The atom numbering corresponds to the 2H -thiocin nomenclature.

Compound	X	NMR	$\text{CH}_2(2)$	$\text{CH}_2(3)$	$\text{CH}_2(4)$	C(5,6)	$\text{CH}_2(7)$	$\text{CH}_2(8)$
9	S	$\delta(\text{H})$	2.76–2.72	2.19–2.12	2.24–2.19		2.35–2.29	2.97–2.93
		$\delta(\text{C})$	35.5	35.9	19.6	94.1, 92.2	23.6	41.9
<i>rac</i> - 16	SO	$\delta(\text{H})$	3.59–3.50	2.23–2.30	2.22–2.14		2.74–2.65	3.72–3.65
			2.88–2.80	2.23–2.30	2.12–2.04		2.42–2.32	3.06–3.02
		$\delta(\text{C})$	62.0	25.8	18.5	92.1, 88.7	15.6	60.8
17	SO_2	$\delta(\text{H})$	3.37–3.33	2.36–2.28	2.26–2.20		2.61–2.55	3.55–3.51
		$\delta(\text{C})$	61.9	25.3	18.7	92.1, 88.9	16.0	59.9



Scheme 3



Alder reactions with subsequent aromatization according to the *Alder–Rickert* rule furnished the cycloadducts **20**, **21**, and **22**, respectively, in reasonable-to-good yields.

From a synthetic point of view, the 1,3-dipolar cycloaddition, another $[2\pi + 4\pi]$ cycloaddition, of **8**, **16**, and **17** with CH_2N_2 is more attractive. The tautomeric pyrazoles **23–28** were obtained (Scheme 4). The regioselectivities **23/24**, **25/26**, and **27/28** change from 3:2 for the reaction of **9** to 1:3 for the reaction of the sulfone **17**. NOE Experiments served for the distinction between the isomeric pyrazoles. Irradiation into the signal of $\text{H}-\text{C}(3)$ led to a positive NOE for $\text{CH}_2(4)$, which is a part of the ethylene ‘chain’ in **23**, **25**, and **27**, whereas it is a part of the trimethylene ‘chain’ in **24**, **26**, and **28**.


Finally, we studied the behavior of the alkynes toward CS_2 (Scheme 5). Alkyne **9** furnished, after 12 d in boiling CS_2 , tetrathiafulvalene **29** in low yield. This reaction type is restricted to strained cycloalkynes and to electron-deficient linear alkynes [47][48]. A second reaction product of **9** (obtained in a yield of 16%) had the formula $\text{C}_{23}\text{H}_{30}\text{S}_7$, which corresponds to a 3:2-adduct of **9** and CS_2 . Sulfoxide **16** gave 41% of the tetrathiafulvalene **30**. (*Z/E*)-Isomers have to be considered for **29** and **30**. It is known that the separation of (*Z/E*)-isomeric tetrathiafulvalenes is extremely difficult – even a spectroscopic identification of these isomers is challenging [49]. We found a single set of ^{13}C -NMR signals among which the broad signal at $\delta(\text{C})$ 108.2 looked like two superimposed signals for C(2) of **29**. All other ^{13}C -NMR signals of **29** did not show a



splitting. Apart from the (*Z/E*)-isomerism, **30** exhibits a stereoisomerism owing to the sulfoxide functionalities. Compounds *syn*-(*E*)-**30** and *anti*-(*Z*)-**30** are chiral, and *anti*-(*E*)-**30** and *syn*-(*Z*)-**30** are *meso*-forms. Chiral tetrathiafulvalenes have recently gained a high actuality [50][51]. Most of the ¹³C-NMR signals of **30** are split into pairs of equal intensity. This corresponds to a *syn*-**30**/*anti*-**30** ratio of 1:1. The resonance region at $\delta(\text{C})$ 47.3–47.7 for one of the C-atoms neighboring to the SO group is even split into four signals (*syn*-(*Z*), *anti*-(*Z*), *syn*-(*E*), and *anti*-(*E*)); see *Exper. Part*). The other C-atom neighboring to the SO group gives two signals of 52.6 ppm. Sulfone **17** did not show an addition of CS₂ with subsequent tetrathiafulvalene generation.

Conclusions. – In principle, three isomeric thiacyclooctynes (=didehydrotetrahydro-2*H*-thiocins), and their sulfoxides and sulfones should exist. 1-Thiacyclooct-2-yne and -3-yne were synthesized much earlier; here we report the preparation of 1-

thiacyclooct-4-yne (**9**) by applying the seleniadiazole method for the formation of the C≡C bond. Oxidation of **9** with NaIO₄ generated the sulfoxide **16** and the sulfone **17**.



Other sulfoxides or sulfones ($n = 0, 1$) of thiacyclooctynes are not known. All three heterocyclic alkynes, **9**, **16**, and **17**, have high reactivities as 2π components toward 4π components in *Diels–Alder* reactions and 1,3-dipolar cycloadditions. Moreover, the tetrathiafulvalenes **29** and **30** could be obtained from **9** and **16** by the reaction with CS₂. The new cyclic alkynes **9**, **16**, and **17** are stimulating candidates for click reactions and should be also interesting species for applications in bioorthogonal processes.

We are grateful to the *Deutsche Forschungsgemeinschaft* and the *Fonds der Chemischen Industrie* for financial support.

Experimental Part

General. 4,7,8,9-Tetrahydro-5H-thiocino[5,4-d][1,2,3]seleniadiazole (**8**) was prepared as described in [45] from 5-thiocanone (**6**) via semicarbazone **7**. M.p.: Büchi melting-point apparatus. IR: Beckman Acculab 4; $\bar{\nu}$ in cm⁻¹. ¹H- and ¹³C-NMR spectra: AM-400 spectrometer from Bruker; CDCl₃ as solvent and Me₄Si as internal standard; δ in ppm and *J* in Hz. EI-MS: Finnigan-MAT-95 spectrometer, 70-eV ionization energy; in *m/z* (rel. %).

Thermal Fragmentation of 1,2,3-Seleniadiazole 8. To 2.0 g (31.5 mmol) of Cu powder, 467 mg (2.0 mmol) of **8** dissolved in 2 ml of CH₂Cl₂ was added. The solvent was removed, and the residue was heated under reduced pressure of 100 Pa to 170 ± 5°. 5-Thiacyclooctyne (5,6-didehydro-3,4,7,8-tetrahydro-2H-thiocin; **9**) distilled off as a colorless oil. Yield 235 mg (93%). IR (CDCl₃): 2240 (C≡C). NMR: see the Table. EI-MS: 126 (62, *M*⁺), 111 (51), 98 (52), 97 (100). According to the NMR spectra, the product was pure, but, due to the volatility, a correct combustion analysis could not be conducted.

Thiocan-5-one 1-Oxide (=1-Oxo-1λ⁴-thiocan-5-one) (10). The preparation was performed according to a modified procedure described by Leonard and Johnson [54]. Thiocanone **8** (1.00 g, 6.93 mmol) was dissolved in 10 ml of MeOH and added at 0° within 20 min to a soln. of 1.58 g (7.39 mmol) of NaIO₄ in 10 ml of H₂O. The product was isolated by extraction with CHCl₃. The hygroscopic compound melted at 105° (m.p. 91–92° [54]) and was analytically pure. Yield 1.05 g (95%). IR (CDCl₃): 1030 (S=O), 1695 (C=O). ¹H-NMR (CDCl₃): 3.17–3.08 (*ddd*, ²*J* = 14.4, ³*J* = 8.8, ³*J* = 2.6, 1 H each, CH₂(2,8)); 2.73–2.57 (*m*, 1 H each, CH₂(2,4,6,8)); 2.43–2.28 (*m*, 1 H each, CH₂(3,4,6,7)); 2.15–2.04 (*m*, 1 H each, CH₂(3,7)). ¹³C-NMR (CDCl₃): 213.4 (C(5)); 51.1 (C(2,8)), 40.5 (C(4,6)); 18.1 (C(3,7)). EI-MS: 160 (7, *M*⁺), 118 (24), 90 (100). Anal. calc. for C₇H₁₂O₂S (160.2): C 52.47, H 7.55; found: C 52.58, H 7.57.

Thiocan-5-one 1,1-Dioxide (=1,1-Dioxo-1λ⁶-thiocan-5-one) (11). The preparation was conducted according to a modified procedure described by Leonard *et al.* [54][55]. Thiocanone **8** (1.00 g, 6.93 mmol) dissolved in 20 ml of acetone was treated with H₂O₂ (30%, 1.40 g, 73.6 mmol) at r.t. The reaction was monitored by TLC (SiO₂, CH₂Cl₂). At the end, the volatile parts were removed and the residue was recrystallized from EtOH. Yield 904 mg (74%). M.p. 106° ([55]: 124–127°). IR (KBr): 1690 (C=O), 1325 (SO₂), 1125 (SO₂). ¹H-NMR (CDCl₃): 3.15–3.08 (*m*, 4 H, CH₂(2,8)); 2.66–2.60 (*m*, 4 H, CH₂(4,6)); 2.33–2.24 (*m*, 4 H, CH₂(3,7)). ¹³C-NMR (CDCl₃): 212.8 (C(5)); 54.8 (C(2,8)); 39.8 (C(4,6)); 19.9 (C(3,7)). EI-MS: 176 (8, *M*⁺), 70 (56), 55 (42), 42 (100). The compound was identical with an authentic sample [54][55].

rac-2-(1-Oxidothiocan-5-ylidene)hydrazinecarboxamide (*rac*-**12**). Semicarbazide hydrochloride (950 mg, 8.5 mmol) and AcONa (1.08 g, 13.2 mmol) were briefly refluxed in 20 ml of dry EtOH. The hot filtrate was added to **10** (1.12 g, 7.0 mmol) dissolved in 5 ml of dry EtOH. After 2 h, the mixture was cooled to 0°. A crystalline precipitate was formed which was recrystallized from MeOH. Yield: 1.25 g (82%). Colorless, fine crystals. M.p. 138°. IR (KBr): 1660 (C=O), 1010 (S=O). ¹H-NMR ((D₆)DMSO): 9.12 (s, NH); 6.26 (s, NH₂); 3.10–3.01 (m, 1 H); 2.95–2.83 (m, 2 H); 2.63–2.52 (m, 2 H); 2.35–2.27 (m, 1 H); 2.27–2.08 (m, 3 H); 2.06–1.95 (m, 2 H); 1.92–1.81 (m, 1 H). ¹³C-NMR ((D₆)DMSO): 157.1 (CO); 150.2 (C(5)); 51.3, 50.6 (C(2,8)); 35.6 (C(6)); 26.4 (C(4)); 18.9, 16.4 (C(3,7)). EI-MS: 217 (91, M⁺), 166 (56), 160 (100). Anal. calc. for C₈H₁₅N₃O₂S (217.3): S 44.22, H 6.69, N 19.34; found: C 44.16, H 6.98, N 19.29.

2-(1,1-Dioxidothiocan-5-ylidene)hydrazinecarboxamide (**13**). The preparation was performed as described for **12**. Ketone **11** (2.33 g, 13.2 mmol) yielded 2.46 g (80%) of **13**. Colorless crystals. M.p. 184° (MeOH). IR (KBr): 1680 (C=O), 1110 (SO₂). ¹H-NMR ((D₆)DMSO): 9.10 (s, NH); 6.30 (s, NH₂); 3.22–3.14 (m, 2 H); 3.05–2.96 (m, 2 H); 2.54–2.45 (m, 2 H); 2.38–2.29 (m, 2 H); 2.08–1.95 (m, 4 H). ¹³C-NMR ((D₆)DMSO): 157.2 (CO); 149.7 (C(5)); 53.6, 53.1 (C(2,8)); 35.5, 25.8 (C(4,6)); 20.8, 17.6 (C(3,7)). EI-MS: 233 (8, M⁺), 97 (24), 83 (37), 67 (30), 44 (43), 41 (100). Anal. calc. for C₈H₁₅N₃O₃S (233.3): C 41.19, H 6.48, N 18.01; found: C 41.08, H 6.49, N 17.97.

rac-4,7,8,9-Tetrahydro-5H-thiocino[5,4-d][1,2,3]selenadiazole 6-Oxide (*rac*-**14**). To semicarbazone **12** (870 mg, 4.0 mmol) in 55 ml of dioxane, SeO₂ (0.89 g, 8.0 mmol) and 0.25 ml of H₂O were added. The reaction in the dark was monitored by TLC (SiO₂, toluene). After ca. 2 d, when the formation of gas (CO₂, NH₃) was completed, the mixture was filtered and concentrated to ca. 3 ml. The remaining red oil was purified by column chromatography CC (SiO₂ (2 × 50 cm); toluene/AcOEt 10:1). Yield: 510 mg (51%). Beige crystals. M.p. 107–108° (dec.). IR (KBr): 1300, 1275, 1025 (S=O), 1000, 990, 780. ¹H-NMR (CDCl₃): 3.78–3.69 (m, 1 H of CH₂(4)); 3.43–3.35 (m, 1 H, CH₂(4)); 3.35–3.29 (m, 1 H, CH₂(9)); 3.29–3.25 (m, 1 H, CH₂(9)); 3.25–3.20 (m, 1 H of CH₂(5)); 3.09–3.03 (m, 1 H of CH₂(7)); 3.03–2.96 (m, 1 H, CH₂(5)); 2.50–2.41 (m, 1 H, CH₂(7)); 2.41–2.31 (m, 1 H, CH₂(8)); 2.31–2.20 (m, 1 H, CH₂(8)). ¹³C-NMR (CDCl₃): 159.3 (C(9a)); 157.0 (C(3a)); 53.6, 48.1 (C(5,7)); 25.2, 23.6, 17.7 (C(4,8,9)). EI-MS: 205 (100, [M – C₃H₈]⁺), 166 (38), 143 (11, [M – N₂ – Se]⁺), 124 (72), 91 (52). Anal. calc. for C₇H₁₀N₂OSSe (249.2): C 33.74, H 4.04, N 11.24; found: C 33.66, H 4.00, N 11.27.

4,7,8,9-Tetrahydro-5H-thiocino[5,4-d][1,2,3]selenadiazole 6,6-Dioxide (**15**). The preparation was performed as described for **14**. Semicarbazone **13** (0.93 g, 4.0 mmol) yielded 920 mg (87%) of **15**. Yellow crystals. M.p. 163°. IR (KBr): 1270 (SO₂), 1165, 1110 (SO₂), 795, 680. ¹H-NMR (CDCl₃): 3.60–3.54 (m, CH₂(4)); 3.47–3.42 (m, CH₂(9)); 3.33–3.27 (m, CH₂(5)); 2.89–2.83 (m, CH₂(7)); 2.19–2.27 (m, CH₂(8)). ¹³C-NMR (CDCl₃): 159.2, 156.1 (C(3a,9a)); 58.6, 53.3 (C(5,7)); 23.9, 22.9, 21.0 (C(4,8,9)). EI-MS: 186 (1, [M – Se]⁺), 119 (39), 92 (39), 91 (100). Anal. calc. for C₇H₁₀N₂O₂SSe (317.0): C 31.70, H 3.80, N 10.56; found: C 31.78, H 3.61, N 10.58.

Oxidation of 4,5-Didehydro-3,6,7,8-tetrahydro-2H-thiocine (**9**). Alkyne **9** (100 mg, 0.79 mmol) was dissolved in 4 ml of MeOH and cooled to 0°. NaIO₄ (712 mg, 3.32 mmol) in 4 ml of H₂O was added, and the mixture was stirred overnight at 0°. Further 6 ml of MeOH were added, and the mixture was cooled to –20°. The inorg. salts precipitated and were filtered off. The soln. was dried (MgSO₄), concentrated, and subjected to CC (SiO₂ (1 × 20 cm); AcOEt/EtOH 2:1). The first fraction consisted of 46 mg (37%) of 4,5-didehydro-3,6,7,8-tetrahydro-2H-thiocine 1,1-dioxide (**17**). Colorless crystals. M.p. 113°. The second fraction consisted of 48 mg (43%) of 4,5-didehydro-3,6,7,8-tetrahydro-2H-thiocine 1-oxide (*rac*-**16**). Colorless crystals. M.p. 56°.

Data of *rac*-**16**. IR (KBr): 1010 (S=O), 2240 (C≡C). ¹H- and ¹³C-NMR: see the Table. EI-MS: 142 (54, M⁺), 91 (48), 79 (75), 77 (100). Anal. calc. for C₇H₁₀OS (142.2): C 59.12, H 7.09, S 22.54; found: C 59.23, H 7.11, S 22.50.

Data of **17**. IR (KBr): 1110 (SO₂), 1275, 1310 (SO₂), 2260 (C≡C). ¹H- and ¹³C-NMR: see the Table. EI-MS: 158 (100, M⁺), 117 (57), 83 (100). Anal. calc. for C₇H₁₀O₂S (158.2): C 53.14, H 6.37; found: C 53.03, H 6.28.

Alkaline Fragmentation of *rac*-**14**. To *rac*-**14** (250 mg, 1.0 mmol) in 10 ml of dry THF, 0.6 ml (1.5 mmol) of a 15% soln. of BuLi in hexane was added at –70°. After 10 min, the reaction was quenched by addition of 1.2 ml of MeOH and 1.2 ml of H₂O. Extraction with CHCl₃ at r.t. gave a yellow

soln., which was dried (MgSO_4), concentrated, and purified by CC (SiO_2 (1×20 cm); AcOEt/EtOH 2 : 1). The first fraction consisted of *rac*-**18** (yield 60 mg (21%), yellow oil), and the second fraction of *rac*-**16** (yield 11.5 mg (8%)).

rac-(5*E*)-6-(*Butylselanyl*)-3,4,7,8-tetrahydro-2H-thiocine 1-Oxide (*rac*-**18**). IR (neat): 1025 (S=O). $^1\text{H-NMR}$ (CDCl_3): 5.62 (*t*, $^3J=9.0$, H-C(5)); 3.34–3.25 (*m*, 1 H, $\text{CH}_2(8)$); 3.25–3.15 (*m*, 1 H, $\text{CH}_2(2)$); 3.00–2.89 (*m*, 1 H each, $\text{CH}_2(7,8)$); 2.80–2.73 (*m*, 1 H, $\text{CH}_2(2)$); 2.67 (*t*, $^3J=7.5$, $\alpha\text{-CH}_2$); 2.60–2.52 (*m*, 1 H, $\text{CH}_2(7)$); 2.44–2.33 (*m*, 1 H of $\text{CH}_2(4)$); 2.20–2.08 (*m*, 1 H, $\text{CH}_2(4)$); 2.02–1.91 (*m*, 1 H, $\text{CH}_2(3)$); 1.62 (*quint.*, $^3J=7.5$, $\beta\text{-CH}_2$); 1.38 (*sext.*, $^3J=7.8$, $\gamma\text{-CH}_2$); 0.90 (*t*, $^3J=7.8$, Me). $^{13}\text{C-NMR}$ (CDCl_3): 130.9 (C(6)); 128.8 (C(5)); 52.9, 51.4 (C(2,8)); 31.9, 27.2, 25.3, 25.1, 23.0, 23.0 (other CH_2); 13.5 (Me). EI-MS: 280 (3, M^+ , Se pattern), 143 (100, $[M - \text{C}_4\text{H}_9]^+$). Anal. calc. for $\text{C}_{11}\text{H}_{20}\text{OSSe}$ (279.3): C 47.30, H 7.22; found: C 47.43, H 7.12.

Reaction of **9**, *rac*-**16**, and **17** with 2,3,4,5-Tetraphenylcyclopenta-2,4-dien-1-one (**19**). Alkyne **9**, *rac*-**16** or **17** (0.20 mmol), and **19** (154 mg, 0.40 mmol) were stirred overnight at r.t. in 4 ml of toluene. The violet soln. was concentrated and purified by CC (SiO_2 (1×60 cm); toluene for **20**, AcOEt/EtOH 1 : 1 for **21**, and CHCl_3 for **22**).

1,4,5,6-Tetrahydro-7,8,9,10-tetraphenyl-2H-3-benzothiocine (**20**). Yield: 45 mg (46%). Colorless crystals. M.p. 224°. IR (KBr): 700, 740. $^1\text{H-NMR}$ (CDCl_3): 7.19–7.00 (*m*, 10 arom. H); 6.80–6.66 (*m*, 10 arom. H); 3.10–2.98 (*m*, $\text{CH}_2(1,6)$); 2.68–2.61, 2.60–2.50 (*m*, $\text{CH}_2(2,4)$); 1.65–1.56 (*m*, $\text{CH}_2(5)$). $^{13}\text{C-NMR}$ (CDCl_3): 141.2, 141.2, 141.1, 141.0, 140.7, 140.6, 139.9, 139.6, 137.7, 137.2 (arom. C_q); 131.1, 130.7, 130.4, 127.4, 127.2, 126.3, 126.1, 126.0, 125.0 (arom. CH, partly superimposed); 35.1, 33.9, 32.5, 31.0, 27.5 (aliph. CH_2). EI-MS: 482 (89, M^+), 440 (100). Anal. calc. for $\text{C}_{35}\text{H}_{30}\text{S}$: C 87.09, H 6.26; found: C 87.21, H 6.52.

1,4,5,6-Tetrahydro-7,8,9,10-tetraphenyl-2H-3-benzothiocine 3-Oxide (**21**). Yield 59 mg (59%). Colorless crystals. M.p. 227°. IR (KBr): 700, 740, 1025 (S=O). $^1\text{H-NMR}$ (CDCl_3): 7.34–6.97 (*m*, 10 arom. H); 6.82–6.66 (*m*, 10 arom. H); 3.31–3.15, 3.08–2.85, 2.81–2.63 (*m*, $\text{CH}_2(1,2,4,6)$); 1.97–1.79 (*m*, $\text{CH}_2(5)$). $^{13}\text{C-NMR}$ (CDCl_3): 141.5, 141.4, 140.8, 140.4, 140.3, 140.2, 140.1, 140.1, 135.7, 135.4 (arom. C_q); 130.9, 130.3, 130.2, 130.1, 127.7, 127.5, 127.3, 126.5, 126.4, 126.3, 125.2 (arom. CH, partly superimposed); 58.3, 55.3 (C(2,4)); 28.5, 23.5, 22.8 (C(1,5,6)). EI-MS: 498 (97, M^+), 407 (100). Anal. calc. for $\text{C}_{35}\text{H}_{30}\text{OS}$ (498.7): C 84.30, H 6.06; found: C 84.05, H 6.05.

1,4,5,6-Tetrahydro-7,8,9,10-tetraphenyl-2H-3-benzothiocine 3,3-Dioxide (**22**). Yield: 87 mg (84%). Colorless crystals. M.p. 255°. IR (KBr): 700, 740, 1120 (SO_2), 1280 (SO_2). $^1\text{H-NMR}$ (CDCl_3): 7.21–7.00 (*m*, 10 arom. H); 6.83–6.68 (*m*, 10 arom. H); 3.15–2.97 (*m*, $\text{CH}_2(1,2,4,6)$); 1.71–1.67 (*m*, $\text{CH}_2(5)$). $^{13}\text{C-NMR}$ (CDCl_3): 141.6, 141.5, 141.0, 140.4, 140.2, 140.1, 140.0, 139.9, 135.5, 135.2 (arom. C_q); 130.8, 130.2, 129.9, 127.8, 127.5, 126.7, 126.5, 125.3 (arom. CH, partly superimposed); 58.7, 52.5 (C(2,4)); 27.1, 24.6, 22.6 (C(1,5,6)). EI-MS: 514 (43, M^+), 349 (56), 348 (50), 347 (100). Anal. calc. for $\text{C}_{35}\text{H}_{30}\text{O}_2\text{S}$ (514.7): C 81.68, H 5.87; found: C 81.51, H 5.68.

Reaction of **9**, *rac*-**16**, and **17** with CH_2N_2 . To 0.50 mmol of the **9**, *rac*-**16**, or **17**, dissolved in 10 ml of dry Et_2O , a 0.1 M soln. of CH_2N_2 in Et_2O (ca. 10 ml, ca. 1.0 mmol) was added. The yellow soln. was stirred for 24 h, and then the excess CH_2N_2 was removed by passing compressed air through the flask (the air is then introduced to a trap with aq. HCl). The remaining soln. was concentrated, and the product was purified by CC (SiO_2 (2×38 cm); Et_2O /petroleum ether (b.p. 40–70°) 3 : 1). The separation of the regioisomeric cycloadducts **23/24**, *rac*-**25/26**, and **27/28** by CC was not successful. The correlation of the NMR signals was based on NOE experiments and $^1\text{H}, ^1\text{H-COSY}$ 45 spectra.

1,4,5,7,8,9-Hexahydrothiocino[5,4-*c*]pyrazole (**23**)/1,4,5,6,8,9-Hexahydrothiocino[4,5-*c*]pyrazole (**24**). Yield: 49 mg (58%). Colorless crystals. M.p. 96°. Ratio **23/24** according to the $^1\text{H-NMR}$ signals 60 : 40. $^1\text{H-NMR}$ (CDCl_3) of **23**: 7.25 (*s*, H-C(3)); 3.04–2.99 (*m*, $\text{CH}_2(9)$); 2.88–2.85 (*m*, $\text{CH}_2(4)$); 2.67–2.63 (*m*, $\text{CH}_2(5)$); 2.47–2.43 (*m*, $\text{CH}_2(7)$); 1.89–1.81 (*m*, $\text{CH}_2(8)$). $^1\text{H-NMR}$ (CDCl_3) of **24**: 7.28 (*s*, H-C(3)); 3.07–3.03 (*m*, $\text{CH}_2(9)$); 2.76–2.81 (*m*, $\text{CH}_2(4)$); 2.71–2.67 (*m*, $\text{CH}_2(8)$); 2.43–2.39 (*m*, $\text{CH}_2(6)$); 1.78–1.70 (*m*, $\text{CH}_2(5)$). $^{13}\text{C-NMR}$ (CDCl_3) of **23**: 144.8 (C(9a)); 133.4 (C(3a)); 118.1 (C(3)); 37.3, 31.4, 31.2, 28.0, 21.3 (C(4,5,7,8,9)). $^{13}\text{C-NMR}$ (CDCl_3) of **24**: 146.4 (C(9a)); 132.4 (C(3a)); 116.9 (C(3)); 35.4, 32.4, 31.5, 30.1, 19.2 (C(4,5,6,8,9)). EI-MS: 168 (100, M^+), 121 (39), 107 (50), 94 (84). Anal. calc. for $\text{C}_8\text{H}_{12}\text{N}_2\text{S}$ (168.3): C 57.11, H 7.19, N 16.65; found: C 57.00, H 7.18, N 16.68.

rac-1,4,5,7,8,9-Hexahydrothiocino[5,4-*c*]pyrazole 6-Oxide (**25**)/*rac*-1,4,5,6,8,9-Hexahydrothiocino[4,5-*c*]pyrazole 7-Oxide (**26**). Yield: 45 mg (49%). Viscous oil. Ratio **25/26** according to the ¹H-NMR signals 50:50. IR (neat): 1010 (S=O). ¹H-NMR (CDCl₃): 7.35 (s, H–C(3)) and 7.25 (s, H–C(3)); 3.32–2.95 (m, 9 H), 2.92–2.78 (m, 2 H), 2.73–2.62 (m, 4 H), 2.52–2.42 (m, 1 H), 2.21–2.05 (m, 3 H), 2.04–1.93 (m, 1 H). ¹³C-NMR (CDCl₃): 145.3, 144.6 (C(9a)); 132.5, 130.9 (C(3a)); 115.6, 115.5 (C(3)); 55.8, 54.0, 51.5, 51.2 (C(5,7) of **25** and C(6,8) of **26**); 25.0, 23.6, 23.2, 21.1, 18.2, 16.0 (C(4,8,9) of **25** and C(4,5,9) of **26**). EI-MS: 184 (22, M⁺), 108 (12), 85 (66), 84 (21), 83 (100). Anal. calc. for C₈H₁₂N₂O₂S (184.3): C 52.15, H 6.56, N 15.20; found: C 52.40, H 6.85, N 15.17.

1,4,5,7,8,9-Hexahydrothiocino[5,4-*c*]pyrazole 6,6-Dioxide (**27**)/1,4,5,6,8,9-hexahydrothiocino[4,5-*c*]pyrazole 7,7-Dioxide (**28**). Yield 38 mg (38%). Viscous oil. Ratio **27/28** according to the ¹H-NMR signals 25:75. IR (CHCl₃): 1105 (SO₂), 1270 (SO₂). ¹H-NMR (CDCl₃, **27**): 7.40 (s, H–C(3)); 3.21–3.14, 3.02–2.90, 2.03–2.01 (3m, CH₂(4,5,7,8,9)). ¹H-NMR (CDCl₃, **28**): 7.32 (s, H–C(3)), 3.28–3.23, 3.21–3.14, 2.96–2.88, 2.83–2.77, 2.01–1.93 (5m, CH₂(4,5,6,8,9)). ¹³C-NMR (CDCl₃, **27**): 145.2 (C(9a)); 130.2 (C(3a)); 116.1 (C(3)); 59.7, 52.9 (C(5,7)); 23.1, 21.4, 18.2 (C(4,8,9)). ¹³C-NMR (CDCl₃, **28**): 147.0 (C(9a)); 129.8 (C(3a)); 115.9 (C(3)); 58.2, 52.5 (C(6,8)); 24.5, 20.8, 19.1 (C(4,5,9)). EI-MS: 200 (1, M⁺), 84 (93), 66 (100). Anal. calc. for C₈H₁₂N₂O₂S (200.3): C 47.98, H 6.04, N 13.99; found: C 47.88, H 6.30, N 14.02.

Reaction of the 9 or rac-16 with CS₂. Alkyne (1.0 mmol) and CS₂ (4 ml, 5.08 g, 66.7 mmol) were refluxed under N₂ for 12–15 d. The colorless soln. turned orange and then redbrown. The soln. was concentrated, and the products were purified by CC (SiO₂ (3 × 40 cm); toluene/petroleum ether (b.p. 40–70°) 2:1 for **29** and AcOEt/EtOH 1:1 for product **30**).

(2*Z*/E)-4,7,8,9-Tetrahydro-2-(4,7,8,9-tetrahydro-5H-1,3-dithiolo[4,5-*d*]thiicin-2-ylidene)-5H-1,3-dithiolo[4,5-*d*]thiicine; **29**). Yield: 53 mg (13%). Red-orange crystals. M.p. 195°. IR (CDCl₃): 1270, 1445. ¹H-NMR (CDCl₃): 2.75–2.63 (m, CH₂(4,5,7,9,4',5',7',9')); 1.91–1.81 (m, CH₂(8,8')). ¹³C-NMR (CDCl₃): 128.8, 128.7 (C(3a,9a,3a',9a')); 108.2 (C(2,2')); 34.7, 32.0, 31.4, 31.1, 25.1 (C(4,5,7,8,9,4',5',7',8',9')). EI-MS: 404 (100, M⁺), 202 (4, M²⁺). Anal. calc. for C₁₆H₂₀S₆ (404.7): C 47.49, H 4.98; found: C 47.39, H 4.89. As second fraction, a dark-red solid C₂₃H₃₀S₇ (85 mg, 16%) was obtained. The structure was not determined.

syn-(2*Z*/E)- and anti-(2*Z*/E)-4,7,8,9-Tetrahydro-2-(4,7,8,9-tetrahydro-6-oxido-5H-1,3-dithiolo[4,5-*d*]thiicin-2-ylidene)-5H-1,3-dithiolo[4,5-*d*]thiicine 6-Oxide; **30**). Yield: 179 mg (41%). Red-orange solid. M.p. 204°. IR (KBr): 1010, 1445, 1625. ¹H-NMR (CDCl₃): 3.30–3.19 (m, 2 H); 3.19–3.07 (m, 4 H); 3.00–2.89 (m, 2 H); 2.88–2.73 (m, 4 H); 2.55–2.45 (m, 2 H); 2.42–2.30 (m, 2 H); 2.26–2.20 (m, 2 H); 2.20–2.13 (m, 2 H) (CH₂ groups). ¹³C-NMR (CDCl₃): 129.0, 129.0, 127.3, 127.2 (C(3a,9a,3a',9a')); 108.3, 108.2 (C(2,2')); 52.6, 52.6, 47.7, 47.6, 47.4, 47.3 (C(5,7,5',7')); 26.5, 26.4, 23.0, 22.8, 18.9, 18.8 (C(4,8,9,4',8',9')). EI-MS: 436 (30, M⁺), 142 (100), 97 (56), 85 (49), 72 (58), 71 (84). Anal. calc. for C₁₆H₂₀O₂S₆ (436.7): C 44.01, H 4.62, S 44.05; found: C 43.89, H 4.61, S 43.87.

REFERENCES

- [1] J. Tummatorn, P. Batsomboon, R. J. Clark, I. V. Alabugin, G. B. Dudley, *J. Org. Chem.* **2012**, *77*, 2093.
- [2] W. Chen, D. Wang, C. Dai, D. Hamelberg, B. Wang, *Chem. Commun.* **2012**, *48*, 1736.
- [3] K. Banert, O. Plefka, *Angew. Chem.* **2011**, *123*, 6295; *Angew. Chem., Int. Ed.* **2011**, *50*, 6171.
- [4] V. A. D'yakov, R. A. Tuktarova, L. M. Khalilov, U. M. Dzhemilev, *Tetrahedron Lett.* **2011**, *52*, 4602.
- [5] M. F. Debets, S. S. van Berkel, J. Dommerholt, A. J. Dirks, F. P. J. T. Rutjes, F. L. van Delft, *Accounts Chem. Res.* **2011**, *44*, 805.
- [6] J. Moran, C. S. McKay, J. P. Pezacki, *Can. J. Chem.* **2011**, *89*, 148.
- [7] B. C. Sanders, F. Friscourt, P. A. Ledin, N. E. Mbua, S. Arumugam, J. Guo, T. J. Boltje, V. V. Popik, G.-J. Boons, *J. Am. Chem. Soc.* **2011**, *133*, 949.
- [8] F. Starke, M. Walther, H.-J. Pietzsch, *Arkivoc* **2010**, Part XI, 350.
- [9] E. M. Sletten, H. Nakamura, J. C. Jewett, C. R. Bertozzi, *J. Am. Chem. Soc.* **2010**, *132*, 11799.
- [10] J. C. Jewett, C. R. Bertozzi, *Chem. Soc. Rev.* **2010**, *39*, 1272.

- [11] M. F. Debets, S. S. van Berkel, S. Schoffelen, F. P. J. T. Rutjes, J. C. M. van Hest, F. L. van Delft, *Chem. Commun.* **2010**, 46, 97.
- [12] S. C. Kornmayer, F. Rominger, R. Gleiter, *Synthesis* **2009**, 2547.
- [13] F. Schoenebeck, D. H. Ess, G. O. Jones, K. N. Houk, *J. Am. Chem. Soc.* **2009**, *131*, 8121.
- [14] J. A. Codelli, J. M. Baskin, N. J. Agard, C. R. Bertozzi, *J. Am. Chem. Soc.* **2008**, *130*, 11486.
- [15] R. van Geel, G. J. M. Pruijijn, F. L. van Delft, W. C. Boelens, *Bioconjugate Chem.* **2012**, *23*, 392.
- [16] J.-L. Chabard, C. Krishnamurthy, W. Yi, D. F. Smith, L. C. Hsieh-Wilson, *J. Am. Chem. Soc.* **2012**, *134*, 4489.
- [17] S. Brauch, M. Henze, B. Osswald, K. Naumann, L. A. Wessjohann, S. S. van Berkel, B. Westermann, *Org. Biomol. Chem.* **2012**, *10*, 958.
- [18] H. E. Bostic, M. D. Smith, A. A. Poloukhtine, V. V. Popik, M. D. Best, *Chem. Commun.* **2012**, 48, 1431.
- [19] J. Z. Yao, C. Uttamapinant, A. Poloukhtine, J. M. Baskin, J. A. Codelli, E. M. Sletten, C. R. Bertozzi, V. V. Popik, A. Y. Ting, *J. Am. Chem. Soc.* **2012**, *134*, 3720.
- [20] M. Simon, U. Zangemeister-Wittke, A. Plückthun, *Bioconjugate Chem.* **2012**, *23*, 279.
- [21] S. Arumugam, J. Chin, R. Schirmacher, V. V. Popik, A. P. Kostikov, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 6987.
- [22] M. Liong, M. Fernandez-Suarez, D. Issadore, C. Min, C. Tassa, T. Reiner, S. M. Fortune, M. Toner, H. Lee, R. Weissleder, *Bioconjugate Chem.* **2011**, *22*, 2390.
- [23] J. C. Jewett, C. R. Bertozzi, *Org. Lett.* **2011**, *13*, 5937.
- [24] E. M. Sletten, C. R. Bertozzi, *J. Am. Chem. Soc.* **2011**, *133*, 17570.
- [25] R. D. Carpenter, S. H. Hausner, J. L. Sutcliffe, *ACS Med. Chem. Lett.* **2011**, *2*, 885.
- [26] V. Bouvet, M. Wuest, F. Wuest, *Org. Biomol. Chem.* **2011**, *9*, 7393.
- [27] L. S. Campbell-Verduyn, L. Mirfeizi, A. K. Schoonen, R. A. Dierckx, P. H. Elsinga, B. L. Feringa, *Angew. Chem.* **2011**, *123*, 11313; *Angew. Chem., Int. Ed.* **2011**, *50*, 11117.
- [28] Z. Cheng, D. R. Elias, N. P. Kamat, E. D. Johnston, A. Poloukhtine, V. Popik, D. A. Hammer, A. Tsourkas, *Bioconjugate Chem.* **2011**, *22*, 2021.
- [29] J. C. M. van Hest, L. A. Canalle, R. P. Brinhkuis, S. A. Meeuwissen, *Polym. Prepr. (Am. Chem. Soc., Div. Polym. Chem.)* **2011**, *52*, 415.
- [30] J. Xu, T. M. Fillion, F. Prifti, J. Song, *Chem. Asian J.* **2011**, *6*, 2730.
- [31] D. Lisse, V. Wilkens, C. You, K. Busch, J. Piehler, *Angew. Chem.* **2011**, *123*, 9524; *Angew. Chem., Int. Ed.* **2011**, *50*, 9352.
- [32] C. Besanceney-Webler, H. Jiang, T. Zheng, L. Feng, D. Soriano del Amo, W. Wang, L. M. Klivansky, F. L. Marlow, Y. Liu, P. Wu, *Angew. Chem.* **2011**, *123*, 8201; *Angew. Chem., Int. Ed.* **2011**, *50*, 8051.
- [33] T. Zheng, H. Jiang, M. Gros, D. Soriano del Amo, S. Sundaram, G. Lauvau, F. Marlow, Y. Liu, P. Stanley, P. Wu, *Angew. Chem.* **2011**, *123*, 4199; *Angew. Chem., Int. Ed.* **2011**, *50*, 4113.
- [34] Z. Hao, Y. Song, S. Lin, M. Yang, Y. Liang, J. Wang, P. R. Chen, *Chem. Commun.* **2011**, 47, 4502.
- [35] J. Xu, F. Prifti, J. Song, *Macromolecules* **2011**, *44*, 2660.
- [36] L. A. Canalle, M. van der Knaap, M. Overhand, J. C. M. van Hest, *Macromol. Rapid Commun.* **2011**, *32*, 203.
- [37] A. Kuzmin, A. Poloukhtine, M. A. Wolfert, V. V. Popik, *Bioconjugate Chem.* **2010**, *21*, 2076.
- [38] X. Ning, R. P. Temming, J. Dommerholt, J. Guo, D. B. Ania, M. F. Debets, M. A. Wolfert, G.-J. Boons, F. L. van Delft, *Angew. Chem.* **2010**, *122*, 3129; *Angew. Chem., Int. Ed.* **2010**, *49*, 3065.
- [39] J. C. Jewett, E. M. Sletten, C. R. Bertozzi, *J. Am. Chem. Soc.* **2010**, *132*, 3688.
- [40] K. Chenoweth, D. Chenoweth, W. A. Goddard III, *Org. Biomol. Chem.* **2009**, *7*, 5255.
- [41] E. M. Sletten, C. R. Bertozzi, *Org. Lett.* **2008**, *10*, 3097.
- [42] J.-T. Shin, S. Shin, C.-G. Cho, *Tetrahedron Lett.* **2004**, *45*, 5857.
- [43] J. K. Crandoll, T. A. Ayers, *J. Org. Chem.* **1992**, *57*, 2993.
- [44] H. Meier, *Advances in Strain in Organic Chemistry* **1991**, *1*, 215.
- [45] H. Schuhmacher, H. Meier, *Z. Naturforsch., B* **1992**, *47*, 563.
- [46] H. Meier in M. Hesse, H. Meier, B. Zeeh, (S. Bienz, L. Bigler, T. Fox) 'Spektroskopische Methoden in der organischen Chemie', 8th edn, Thieme Verlag, Stuttgart, 2012, pp. 161–163.

- [47] R. Csuk, B. I. Glänzer, in 'Comprehensive Heterocyclic Chemistry II', Ed. A. R. Katritzky, C. W. Rees, E. F. V. Scriven, I. Shinkai, Elsevier, Oxford, 1996, Vol. 3, p. 651.
- [48] A. Gorgues, P. Hudhomme, M. Sallé, *Chem. Rev.* **2004**, *104*, 5151.
- [49] E. Fanghänel, L. Van Hinh, G. Schukat, A. Herrmann, *J. Prakt. Chem.* **1996**, *338*, 523.
- [50] N. Avarvari, *Actualité Chimique* **2009**, *333*, 18.
- [51] J. L. Segura, N. Martin, *Angew. Chem.* **2001**, *113*, 1416; *Angew. Chem., Int. Ed.* **2001**, *40*, 1372.
- [52] H. Meier, E. Stavridou, C. Storek, *Angew. Chem.* **1986**, *98*, 838; *Angew. Chem., Int. Ed.* **1986**, *25*, 809.
- [53] E. Stavridou, H. Schuhmacher, H. Meier, *Liebigs Ann. Chem.* **1989**, 435.
- [54] N. J. Leonard, C. R. Johnson, *J. Am. Chem. Soc.* **1962**, *84*, 3701.
- [55] N. J. Leonard, T. W. Milligan, T. L. Brown, *J. Am. Chem. Soc.* **1960**, *82*, 4075.

Received May 16, 2012